Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Othman Tamer, Roloff Gregory W, Miller Katharine, Zhang Amy, Sutherland Katherine C, Faramand Rawan, Hill LaQuisa C, Muhsen Ibrahim N, Jeyakumar Nikeshan, Ladha Abdullah, Sasine Josh, Lin Chenyu, Kopmar Noam E, Tsai Stephanie B, O'Connor Timothy E, Hilal Talal, Solh Melhem M, Guzowski Caitlin, Tan Virginia, Majhail Navneet S, Battiwalla Minoo, Malik Shahbaz, Mathews John, Shaughnessy Paul, Mountjoy Luke, Dykes Kaitlyn C, Logan Aaron C, Schwartz Marc, Connor Matthew P, Wang Jiasheng, Vasu Sumithira, Kumaran Muthu, Hoeg Rasmus, Tracy Sean I, Yalniz Fevzi, Yaghmour George, Pullarkat Vinod, Cassaday Ryan D, Leonard Jessica T, Shah Bijal D, Frey Noelle V, Muffly Lori S, Aldoss Ibrahim
Аннотация
Brexucabtagene autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adult patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adult patients with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 US institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance vs no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance, and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (hazard ratio [HR], 0.12; 95% confidence interval [CI], 0.02-0.88; P = .037), which translated into improved progression-free survival (PFS; HR, 0.19; 95% CI, 0.04-0.85; P = .029) and a trend toward improved overall survival (HR, 0.34; 95% CI, 0.07-1.62; P = .18). There was no difference in nonrelapse mortality (HR, 0.83; 95% CI, 0.12-5.87; P = .85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL after achievement of MRD- CR with brexu-cel as a strategy to improve PFS after chimeric antigen receptor T-cell therapy.